Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England by Mebrahtu, T et al.
C L I N I C A L R E S E A R C H A R T I C L E
Dose Dependency of Iatrogenic Glucocorticoid
Excess and Adrenal Insufficiency and Mortality:
A Cohort Study in England
Teumzghi F. Mebrahtu,1 Ann W. Morgan,2,3 Adam Keeley,4 Paul D. Baxter,2
Paul M. Stewart,3,5 and Mar Pujades-Rodriguez6
1Leeds Institute of Biomedical and Clinical Sciences, School of Medicine, University of Leeds, Leeds LS2 9NL,
United Kingdom; 2Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University
of Leeds, Leeds LS2 9NL, United Kingdom; 3NIHR Biomedical Research Centre, Leeds Teaching Hospitals
NHS Trust, Chapel Allerton Hospital, Leeds LS2 9NL, United Kingdom; 4Leeds Institute of Data Analytics,
University of Leeds, Leeds LS2 9NL, United Kingdom; 5Dean’s Office, Faculty ofMedicine &Health, University
of Leeds, Leeds LS2 9NL, United Kingdom; and 6Leeds Institute of Health Sciences, School of Medicine,
University of Leeds, Leeds LS2 9NL, United Kingdom
ORCiD numbers: 0000-0003-4821-2304 (T. F. Mebrahtu); 0000-0003-1109-624X (A. W. Morgan);
0000-0003-2699-3103 (P. D. Baxter); 0000-0002-1749-9640 (P. M. Stewart);
0000-0002-1375-1028 (M. Pujades-Rodriguez).
Context: Adrenal insufficiency and Cushing syndrome are known adverse events of glucocorticoids.
However, no population estimates of dose-related risks are available.
Objective: To investigate dose-related risks of adrenal dysfunction and death in adults with six
chronic inflammatory diseases treated with oral glucocorticoids.
Design and setting: Retrospective, record-linkage, open-cohort study spanning primary and
hospital care in England.
Patients: A total of 70,638 oral glucocorticoid users and 41,166 nonusers aged$18 years registered
in 389 practices in 1998 to 2017.
Main outcome measures: Incidence rates and hazard ratios (HRs) of diagnosed adrenal dysfunction
and death.
Results: During a median follow-up of 5.5 years, 183 patients had glucocorticoid-induced adrenal
insufficiency and 248 had glucocorticoid-induced Cushing syndrome. A total of 22,317 (31.6%)
and 7544 (18.3%) deaths occurred among glucocorticoid users and nonusers, respectively. The
incidence of all outcomes increased with higher current daily and cumulative doses. For adrenal
insufficiency, the increases in HRs were 1.07 (95% CI: 1.04 to 1.09) for every increase of 5 mg per
day and 2.25 (95% CI: 2.15 to 2.35) per 1000 mg of cumulative prednisolone-equivalent dose over
the past year. The respective increases in HRs for Cushing syndrome were 1.09 (95% CI: 1.08 to
1.11) and 2.31 (95% CI: 2.23 to 2.40) and for mortality 1.26 (95% CI: 2.24 to 1.28) and 2.05 (95% CI:
2.04 to 2.06).
Conclusion: We report a high glucocorticoid dose-dependent increased risk of adrenal adverse
events and death. The low observed absolute risk of adrenal insufficiency highlights a potential lack
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of awareness and a need for increased physician and patient education about the risks of adrenal
dysfunction induced by glucocorticoids. (J Clin Endocrinol Metab 104: 3757–3767, 2019)
Glucocorticoids are widely used for the treatment ofchronic inflammatory diseases and are administered
through a variety of routes including oral, inhaled, and
topical as well as systemic therapies (1–3). In 2008, it was
estimated that 0.8% of the UK adult population had used
glucocorticoids for 3 months or more, rising to 3% in
women older than 80 years (4). Glucocorticoids are ef-
fective in controlling underlying disease inflammation and
reducing symptoms in the majority of patients with
chronic inflammatory diseases.However, their continuous
use can cause cushingoid features in the context of ex-
ogenous Cushing syndrome with circulating glucocorti-
coid excess (5, 6). Paradoxically, adrenal insufficiency can
also occur because the glucocorticoid excess suppresses
endogenous cortisol secretion by negative feedback
upon the hypothalamo-pituitary-adrenal axis (7–9).
Previous studies have reported absolute risk estimates
for adrenal insufficiency (1, 8, 10) and Cushing syn-
drome (11) in adults treated with glucocorticoids. For
example, a recent meta-analysis including 3753 in-
dividuals receiving glucocorticoid therapy from 36 clinical
trials and 38 observational studies reported an absolute
risk of adrenal insufficiency of 31.7% (48.7% in patients
treated with oral glucocorticoids) (1). Most patients had
atopic diseases (e.g., asthma, rhinitis, dermatitis), cancer,
or organ transplantation, with studies including short,
medium, and long-term glucocorticoid users.
The long-term use of glucocorticoids has also been
associated with a high risk of mortality (12), with many
of the deaths caused by the underlying disease being
treated. However, no estimates of dose-related risk of
adrenal adverse events or mortality are available to guide
and evaluate clinical practice. The aim of this population-
based study was to investigate dose-related risks of ad-
renal insufficiency, Cushing syndrome, and death in
people with underlying chronic inflammatory diseases
commonly treated with oral glucocorticoids.
Materials and Methods
Study population
The study was conducted among patients registered in general
practices of the Clinical Practice Research Datalink (CPRD) who
had consented to data linkage between 1 January 1998 and 15
March 2017. Eligibility criteria for study inclusion were a mini-
mum of 1 year of registration in the practice, age 18 years or older,
and a diagnosis of inflammatory bowel disease, systemic lupus
erythematosus, polymyalgia rheumatica, giant cell arteritis, rheu-
matoid arthritis, and/or vasculitis before or during the studyperiod.
Patient data from three linked data sources spanning pri-
mary and hospital care were used. Primary health care records
from the CPRD (13) were used to identify diagnoses of diseases
(e.g., adrenal insufficiency), prescribed medication, and results
of laboratory tests. Hospital records from the Hospital Epi-
sode Statistics (www.hscic.gov.uk/hes) were used to identify
diagnoses recorded during hospitalization. Data from the
Office for National Statistics (https://www.ons.gov.uk/atoz?
query5mortality&size510) were used to obtain information
on the index of multiple deprivation (14) and to identify dates
and causes of death. Codes used to identify patients with each of
the chronic inflammatory diseases are shown in an online re-
pository (15).
Study design
This is a retrospective, population-based, record-linkage cohort
study. For each patient, the start of follow-up was the earliest date
on which all the eligibility criteria were met. Follow-up ended on
the date of first occurrence of the outcome analyzed (adrenal
insufficiency, Cushing syndrome, or death), de-registration from
the practice, or last date of data collection in the practice,
whichever occurred first. Patients were divided into two groups,
glucocorticoid users and nonusers, according to whether at least
one prescription of glucocorticoids was issued to the patient in the
period between 1 year prior to study start and the end of follow-up.
Outcome variables
The primary outcomes were glucocorticoid-induced adrenal
insufficiency and Cushing syndrome, which were assessed in
the glucocorticoid user population. All-cause mortality was a
secondary outcome, and it was evaluated among glucocorticoid
users and nonusers.
Algorithms for adrenal insufficiency and Cushing syndrome
case identification were developed to minimize misclassification
of outcome status (15). Patients with one or more diagnostic
codes recorded in any of the three data sources and who received
oral glucocorticoids within 1 year prior to the diagnosis but
no other drugs that might have influenced function of the
hypothalamo-pituitary-adrenal axis (e.g., mifepristone and
megestrol acetate) in the previous 6 months were considered to
have the outcome of interest. Lists of Read and International
Classification of Diseases (versions 9 and 10) codes for adrenal
insufficiency and Cushing syndrome diagnoses and medications
used in the algorithms can be found in the online repository (15).
Figure 1 presents the flowchart of the study and the number
of patients diagnosed with each study outcome.
Oral glucocorticoid exposure
Exposure status was defined using drug prescriptions for any
type of oral glucocorticoids issued in primary care. Current
and cumulative doses were derived from the recorded product
strength (e.g., 5 mg), directions given (e.g., twice daily), and
prescribed quantity (e.g., 100 tablets). Because the relative anti-
inflammatory effects of different types of glucocorticoids vary,
dosages were converted into prednisolone-equivalent doses, with
10 mg of prednisolone considered to be equivalent to 0.96 mg
of beclomethasone, 1.09 mg of budesonide, 1.5 mg of betame-
thasone and dexamethasone, 8 mg of methylprednisolone and
triamcinolone, 10 mg of prednisone, 12mg of deflazacort, 40mg
of hydrocortisone, and 50 mg of cortisone (16).
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To minimize length- and time-dependent bias (17), patient
exposure status was determined by taking into account periods
without prescribed medication. For example, the period be-
tween the start of follow-up and the first recorded oral glu-
cocorticoid prescription (i.e., time at risk) and the periods not
covered by prescribed medication were classified as unexposed.
The end date of each drug prescription was not available and
was calculated by adding the duration of days covered by the
prescription to the date when the prescription was issued. For
each prescription recorded, its duration was calculated as the
number of tablets prescribed divided by the daily dose. When
data on the daily dose or the number of tablets prescribed were
missing, they were imputed using truncated regression (18). The
number of data sets to be imputed was assumed to be at least
100 times the fraction of incomplete cases (19). Hence, a total of
20 data sets were imputed. Variables included for imputation
were nonoral glucocorticoid prescription during follow-up, sex,
baseline comorbidities (hypertension, cardiovascular disease,
and diabetes), and duration of the first recorded underlying
chronic inflammatory disease. The imputed values of daily dose
and number of tablets prescribed were then averaged to replace
the missing values of each variable before estimating the end
date of each prescription and calculating the survival time. This
approach was adopted given that the missing values in the two
variables would affect the survival time and that the incidence of
the adrenal outcomes was very low (0.3% to 0.4%), which
would have biased the Nelson-Aalen estimator and event in-
dicator variables (20).
Three types of time-variant oral glucocorticoid exposure
variables were initially defined (Fig. 2): current daily dose [i.e.,
Figure 1. Study flow diagram and outcome identification. Eligibility inclusion criteria were a minimum of 1 year of registration in the CPRD
practice, consent to data linkage, age $18 years, and a diagnosis of inflammatory bowel disease, systemic lupus erythematosus, polymyalgia
rheumatica, giant cell arteritis, rheumatoid arthritis, and/or vasculitis before or during the study period (1 January 1998 to 15 March 2017).
During periods of nonglucocorticoid exposure, 102 patients had adrenal insufficiency and 94 patients had Cushing syndrome diagnosed at a
median of 52 [interquartile range (IQR): 31 to 79] d and 42 (IQR: 30 to 63) d, respectively, following glucocorticoid discontinuation. ADI, adrenal
insufficiency; CS, Cushing syndrome; GC, glucocorticoid.
Figure 2. Definition of time-variant oral glucocorticoid exposure variables. Inclusion criteria included a diagnosis of inflammatory bowel disease,
systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, and/or vasculitis before or during the study period
(1 January 1998 to 15 March 2017). GC, glucocorticoid; PED, prednisolone equivalent dose.
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the value corresponding to the dose prescribed for the dura-
tion covered by the prescription and changed on the date(s) on
which the prescribed dose increased or decreased]; cumulative
dose in the previous year (i.e., the value was “zero” until 1 year
before the end of follow-up; from that date, it corresponded to
the cumulative prescribed dose during the last year of follow-
up); and cumulative dose since 1 year prior to study entry (i.e.,
the value corresponding to the cumulative prescribed dose
until a given time point and changed with the daily dose
prescribed to the patient during the time of follow-up). Or-
dinal and continuous variables were considered in the ana-
lyses, with cutoff points at 0, 5, and 7.5 mg for current daily
dose and at 0, 960, and 3055 mg for cumulative dose vari-
ables. These cutoffs were based on previous studies (12) to
facilitate comparisons.
Confounding variables
Confounding selection was guided by the epidemiological,
biological, and clinical understanding of the authors. To
minimize bias due to confounding and overadjustment, directed
acyclic graphs were used (21, 22) to select confounding vari-
ables, and models were tested using DAGitty software (23).
This method identified nonoral glucocorticoids (inhaled, intra-
articular, parenteral, nasal, topical, and rectal routes) as the
“minimal sufficient” set of adjustment variables (15). For
mortality, baseline asthma, cancer, heart failure, chronic kidney
disease (stages 4 or 5), time-variant chronic inflammatory
diseases, and prescribed nonoral glucocorticoids during follow-
up were considered confounders (15).
Statistical analysis and software
Dose-specific incidence rates were calculated as the number
of events divided by the total number of person-years at risk.
The incidence ratios of death for patients with adrenal in-
sufficiency and Cushing syndrome, compared with those for
oral glucocorticoid user and nonuser populations, were also
estimated. Furthermore, Kaplan-Meier dose-related risks of
outcomes were reported at 5 and 10 years.
Cox proportional hazard models (24) were used to esti-
mate the risk of glucocorticoid dose-related adrenal dys-
function and mortality. Adjusted and unadjusted models
were constructed for each outcome. Tests of proportional-
hazards assumptions were implemented by interacting the
analysis time with exposure and confounding variables and
verifying that the interaction coefficients were not different
from zero (25). Model convergence was assumed if the best
log-likelihood (global maxima) was achieved. The Bayes-
ian information criterion (26) was used to assess model
“goodness of fit” when comparisons between models was
necessary. Five percent significance levels and 95% confi-
dence intervals were adopted throughout. Information on
confounders and outcomes was complete, so no imputation
was needed. All analyses were carried out with STATA 14.1
software (27).
In sensitivity analyses, dose-related risks of the outcomes
were estimated for each chronic inflammatory disease, and
mixed-effect models were used to account for variation of risk
at the general practice level. Kaplan-Meier estimates of out-
comes were also calculated for patients with prescribed nonoral
glucocorticoids at baseline.
The protocol for the study was approved by the Independent
Scientific Advisory Committee for Medicines and Healthcare
products Regulatory Agency database research, reference
16_146.
Results
Patient characteristics
From 389 general practices, 70,638 eligible gluco-
corticoid users with one of the six chronic inflammatory
diseases were identified. At study entry, the mean age was
59.0 (SD, 17.1) years, and 65.6% were women. Ninety
percent of the patients were white (Table 1). During
follow-up, prednisolone was the most commonly pre-
scribed drug (98.0% of patients).
Polymyalgia rheumatica and/or giant cell arteritis was
the most common underlying inflammatory diseases
(49.6%), followed by rheumatoid arthritis (28.3%). At
baseline, 25.8% of patients had been diagnosed with
asthma and 20.4% had cancer. Inhaled and nasal glu-
cocorticoids had been prescribed in the year prior to
entry for 16.7% and 6.4% of the patients, respectively.
The overall cumulative oral glucocorticoid dose received
by patients during follow-up was 5701 mg (1531 mg
per year). The highest overall cumulative doses were
received by patients with systemic lupus erythematosus
(10,049 mg) and vasculitis (9923 mg) (Table 2). During
follow-up, adrenocorticotropic hormone and cortisol
measurements were recorded for fewer than 1% of
patients.
Adrenal insufficiency
There were 183 patients (0.3%) with adrenal insuffi-
ciency diagnosed over 450,816 person-years of follow-up.
Seventy-one percent of diagnoses were recorded during
hospital admissions and 4.9% in the mortality registry
(Table 3). The median follow-up time per patient was
5.5 years (range, 1.0 month to 19.3 years), and the overall
incidence rate was 0.41 (95% CI: 0.35 to 0.47) per 1000
person-years (Table 4) (15). The crude incidence rate in-
creasedwith higher daily dose (from 0.30 to 0.86 per 1000
person-years for periods of nonuse and for periods with
$7.5 mg/d, respectively) and cumulative dose (from 1.91
to 30.48 for ,960 and $3055 mg/y, respectively, in the
past year). Kaplan-Meier risk estimates at 5 years were
0.9% (95% CI: 0.6% to 1.4%) for ,960 mg and 17.0%
(95% CI: 11.7% to 24.4%) for $3055 mg in the past
year (15).
The risk of adrenal insufficiency increased in periods
with higher levels of daily and cumulative glucocorticoid
exposure (Table 5). The respective increases in adjusted
hazard ratios (HRs) were 1.07 (95% CI: 1.04 to 1.09),
1.09 (95% CI: 1.08 to 1.10), and 2.25 (95% CI: 2.15 to
2.35) for every increase of 5 mg of daily dose, 1000 mg of
overall cumulative dose, and 1000mg of cumulative dose
in the past year.
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Cushing syndrome
There were 248 patients (0.4%) with Cushing syn-
drome during 449,936 person-years of follow-up. Eighty
percent of diagnoses were recorded in primary care and
20.2% during hospital admissions. The median follow-
up time was 5.5 years (range, 1 month to 19.3 years), and
the overall incidence rate of Cushing syndrome was 0.55
per 1000 person-years (95%CI: 0.49 to 0.62). The crude
Table 1. Patient Baseline Characteristics
Characteristics
Oral GC Users
(N 5 70,638)
Oral GC Nonusers
(N 5 41,166)
Sociodemographic information
Age, mean (SD), y 59 (17.1) 52 (18.0)
Men, n (%) 24,476 (34.7) 15,149 (36.8)
Ethnicity, n (%)a
White 63,406 (89.8) 34,331 (83.4)
Black 598 (0.9) 598 (1.5)
Asian 1618 (2.3) 1546 (3.8)
Index of multiple deprivation, n (%)
First (least deprived) 12,543 (17.8) 7221 (17.5)
Fifth (most deprived) 11,378 (16.1) 7282 (17.7)
Body mass index, mean (SD), kg/m2 27.07 (5.6) 26.42 (5.8)
Chronic inflammatory disease, n (%)b
Inflammatory bowel disease 16,598 (23.5) 15,709 (38.2)
Polymyalgia rheumatica and/or giant cell arteritis 35,007 (49.6) 5007 (12.2)
Rheumatoid arthritis 19,995 (28.3) 15,674 (38.1)
Systemic lupus erythematosus 2748 (3.9) 2678 (6.5)
Vasculitis 4367 (6.2) 3785 (9.2)
Biomarkers, median (IQR)
C-reactive protein, mg/L 6 (12) 5 (8.3)
Erythrocyte sedimentation rate, mm/h 17 (24) 13 (21)
Comorbidities, n (%)
Asthma 18,217 (25.8) 5836 (14.2)
Cancer 14,412 (20.4) 5526 (13.4)
Diabetes mellitus 4152 (5.9) 2637 (6.4)
Heart failure 11,489 (16.3) 3334 (8.1)
Chronic kidney disease stage 3 to 4 2211 (3.1) 564 (1.4)
Nonoral prescribed GC in the last y, n (%)
Inhaled 8248 (11.7) 2120 (5.2)
Intramuscular 422 (0.6) 263 (0.6)
Nasal 4491 (6.4) 2040 (5.0)
Topical 1604 (2.3) 830 (2.0)
Rectal 3099 (4.4) 1848 (4.5)
Prescribed daily oral PED at follow-up start,
mean (SD), mg
17.6 (13.8) NA
Abbreviations: GC; glucocorticoid; IQR, interquartile range; NA, not applicable; PED, prednisolone-equivalent dose.
aOther ethnicity (0.6%) and missing (6.3%).
bDiagnosed before or after the start of follow-up. Patients could have more than one disease.
Table 2. Timing of Diagnosis of Underlying Chronic Inflammatory Diseases and Description of Oral
Glucocorticoid Exposure During the Study Period
Chronic Inflammatory
Disease
Diagnosed at
Baseline
Diagnosed During
Follow-Up
Overall Cumulative
Exposure (mg)
Past-y Cumulative
Exposure (mg)
IBD 7912 (50.9) 7627 (49.1) 4001 (52.8) 503 (8.2)
PMR-GCA 7374 (22.8) 24,991 (77.2) 6049 (33.8) 910 (6.7)
Rheumatoid arthritis 7838 (46.1) 9120 (53.8) 6315 (65.9) 934 (9.5)
SLE 1210 (54.7) 1001 (45.3) 6834 (199.8) 982 (27.6)
Vasculitis 959 (26.9) 2606 (73.1) 6329 (155.5) 966 (23.9)
All diseases 25,293 (35.8) 45,345 (64.2) 5701 (27.2) 831 (4.5)
Timing of diagnosis data are shown as n (%); cumulative exposure data are shown as mean (SD) PED.
Abbreviations: IBD, inflammatory bowel disease; PED, prednisolone-equivalent dose; PMR-GCA, polymyalgia rheumatica and/or giant cell arteritis; SLE,
systemic lupus erythematosus.
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incidence rate increased with higher daily dose (from
0.28 to 2.37 per 1000 person-years for nonuse
and $7.5 mg, respectively) and cumulative dose (from
1.86 to 60.90 per 1000 person-years for ,960
and $3055 mg in the past year, respectively). Kaplan-
Meier risk estimates at 5 years were 1.1% (95%CI: 0.7%
to 1.6%) for ,960 mg and 47.1% (95% CI: 38.6% to
56.5%) for $3055 mg in the past year (15).
The risk of Cushing syndrome increased in periods
with higher levels of daily and cumulative exposure. The
increases in adjusted HRs were 1.09 (95% CI: 1.08 to
1.11), 1.10 (95% CI: 1.08 to 1.11), and 2.31 (95% CI:
2.23 to 2.40) for every increase of 5 mg per day, 1000 mg
of the overall cumulative dose over the study period, and
1000 mg of past year cumulative dose, respectively.
Mortality
Patients with prescribed oral glucocorticoids
A total of 22,317 patients (31.6%) with prescribed
oral glucocorticoids during the study period died over
451,146 person-years of follow-up. The median follow-
up period was 5.5 years (range, 1 month to 19.3 years).
Overall, the majority of patients died of cardiovascular
diseases (32.4%), followed by cancer (21.0%) and in-
fection (13.3%) (Table 6). Similar patterns were seen for
all underlying chronic inflammatory diseases.
Table 3. Information on Hospitalization, Endocrinologist Care, and Data Source of Diagnosis for Patients
With Adrenal Dysfunction
Adrenal Insufficiency (N 5 183) Cushing Syndrome (N 5 248) Totala
Source of diagnosis recordinga
Primary care 54 (29.5) 199 (80.2) NA
Hospital admission 130 (71.0) 50 (20.2) NA
Mortality registry 9 (4.9) 0 (0) NA
Hospitalized on date of diagnosis or
within previous 30 d
150 (82.0) 67 (27.0) 216 (50.6)
Endocrinologist care on the date of
diagnosis or within previous 4 mo
6 (3.2) 2 (0.8) 8 (1.9)
Hospitalized in previous 30 d or
endocrinologist care in previous 4 mo
152 (83.0) 68 (27.4) 219 (51.3)
Data are presented as n (%).
Abbreviations: NA, not applicable.
aDiagnoses may be recorded in more than one data source.
Table 4. Observation Time, Overall Incidence Rates, and Time-Variant Oral Glucocorticoid Prednisolone-
Equivalent Dose–Related Incidence Rates of Outcomes
Adrenal Insufficiency Cushing Syndrome Mortality
Total person-y of follow-up 450,816 449,936 451,146
Total incident cases, n (%) 183 (0.3) 248 (0.4) 22, 317 (31.6)
Time at risk per subject, median (IQR), y 5.53 (7.06) 5.52 (7.07) 5.54 (7.07)
Incidence rates per 1000 person-y (95% CI)
Overall 0.41 (0.35–0.47) 0.55 (0.49–0.62) 49.47 (48.82–50.12)
Daily oral dose
Nonuse period 0.30 (0.25–0.37) 0.28 (0.23–0.35) 47.27 (46.55–48.01)
.0 to 4.9 mg 0.60 (0.39–0.94) 0.33 (0.18–0.60) 36.09 (34.10–-38.20)
5.0–7.4 mg 0.58 (0.35–0.99) 0.63 (0.38–1.04) 61.57 (58.50–64.79)
$7.5 mg 0.86 (0.65–1.15) 2.37 (1.99–2.83) 66.38 (64.23–68.61)
Overall cumulative dose
.0 to 959.9 mg 0.08 (0.05–0.16) 0.21 (0.14–0.31) 30.43 (29.46–31.43)
960–3054.9 mg 0.21 (0.14–0.30) 0.64 (0.52–0.80) 42.61 (41.48–43.76)
$3055 mg 0.71 (0.61–0.84) 0.69 (0.58–0.81) 64.68 (63.59–65.78)
Cumulative dose in past y
.0 to 959.9 mg 1.91 (1.37–2.66) 1.86 (1.33–2.60) 272.45 (265.00–280.11)
960–3054.9 mg 9.50 (7.88–11.47) 11.77 (9.94–13.93) 743.19 (727.56–759.17)
$3055 mg 30.48 (22.27–41.71) 60.90 (48.78–76.03) 1,817.94 (1744.80–1894.15)
Past y means 1 y before the end of follow-up. Total time at risk was calculated as the time between the start of follow-up (when all the eligibility criteria
were met) and the end of follow-up (first occurrence of the outcome analyzed, de-registration from practice, or last date of data collection in the practice,
whichever happened first).
Abbreviation: IQR, interquartile range.
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Among patients with prescribed oral glucocorticoids,
mortality rates were similar in patients with and without
adrenal dysfunction (Table 7). However, patients with
adrenal dysfunction had higher mortality rates than
patients who did not receive oral glucocorticoids during
follow-up (incidence rate ratio 5 2.09; 95% CI: 1.64 to
2.63 and incidence rate ratio 5 2.24; 95% CI: 1.84 to
2.69 for adrenal insufficiency and Cushing syndrome,
respectively). The mortality rate increased with higher
daily dose (from 36.09 to 66.38 per 1000 person-years
for periods of .0 to 4.9 mg and $7.5 mg, respectively)
and cumulative dose (from 272.5 to 1818.0 per 1000
person-years for ,960 and $3055 mg in the past year,
respectively). The increases in adjusted HR for every
increase of 5 mg per day, 1000 mg of overall cumulative
dose, and 1000 mg of past year cumulative dose were
1.06 (95% CI: 1.05 to 1.06), 1.03 (95% CI: 1.03 to
1.04), and 2.05 (95% CI: 2.04 to 2.06), respectively.
A total of 74 patients (40.4%) died among patients
with oral glucocorticoid-induced adrenal insufficiency,
contributing 1464 person-years of follow-up. Fifty per-
cent of these deaths occurred within 11 months after
diagnosis (15). Only 13 (15.6%) had their cause of death
recorded as adrenal insufficiency. Infection was recorded
as the primary or auxiliary cause of death in 44.6% of
patients (15). Among patients with oral glucocorticoid-
induced Cushing syndrome who contributed 2072
person-years of follow-up, 112 (45.2%) died. Infection
was recorded as the primary or auxiliary cause of death
in 5.4% of these patients. Fifty percent of these deaths
occurred within 36 months after diagnosis.
Patients without prescribed oral glucocorticoids
During 312,049 person-years of follow-up, a total
of 7544 patients (18.3%) died. The majority died of
cardiovascular diseases (32.3%), followed by cancer
(19.3%) and infection (12.1%).
Sensitivity analyses
Variations in dose-related risks of the outcomes were
examined according to the patient’s underlying chronic
Table 5. Time-Variant Prescribed Prednisolone-Equivalent Dose of Oral Glucocorticoids and the Risks of
Adrenal Insufficiency, Cushing Syndrome, and Death
Hazard Ratios With 95% CI
Adrenal Insufficiencya Cushing Syndromea Mortalityb
Current dose per 5 mg/d 1.07 (1.04–1.09) 1.09 (1.08–1.11) 1.06 (1.05–1.06)
Current dose category (ref: nonuse period)
.0 to 4.9 mg 2.10 (1.29–3.40) 1.20 (0.64–2.25) 0.63 (0.59–0.67)
5.0–7.4 mg 1.94 (1.11–3.41) 2.07 (1.20–3.57) 1.03 (0.98–1.09)
$7.5mg 2.95 (2.07–4.21) 6.64 (5.03–8.78) 1.20 (1.16–1.25)
Overall cumulative dose (per 1000 mg) 1.09 (1.08–1.10) 1.10 (1.08–1.11) 1.03 (1.03–1.04)
Overall cumulative dose category
(ref: .0 to 959.9 mg)
960–3054.9 mg 2.75 (1.32–5.74) 4.24 (2.68–6.69) 1.19 (1.14–1.24)
$3055 mg 14.16 (7.25–27.64) 11.00 (6.95–17.43) 1.64 (1.57–1.71)
Cumulative dose for the past y (per 1000 mg) 2.25 (2.15–2.35) 2.31 (2.23–2.40) 2.05 (2.04–2.06)
Cumulative dose category for the past y
(ref: .0 to 959.9 mg)
960–3054.9 mg 4.98 (3.40–7.30) 6.83 (4.67–9.99) 2.65 (2.56–2.75)
$3055 mg 15.38 (9.72–24.35) 37.03 (24.58–55.78) 6.66 (6.34–7.00)
All estimates were obtained among glucocorticoid users during the study period.
aEstimates adjusted for inhaled, intra-articular, intramuscular, nasogastric, topical, and rectal use of glucocorticoids.
bEstimates additionally adjusted for asthma, cancer, heart failure, chronic kidney disease, and inflammatory diseases (time-variant).
Table 6. Recorded Causes of Death in Patients With and Without Prescribed Oral Glucocorticoids
Recorded Cause of Death
Patients Prescribed Oral
Glucocorticoids
Patients Without Prescribed
Oral Glucocorticoids
Primary cause in all patients N 5 22,317 N 5 7544
Cardiovascular disease 7235 (32.4) 2437 (32.3)
Cancer 4691 (21.0) 1457 (19.3)
Infection 2958 (13.3) 945 (12.1)
Renal disease 354 (1.6) 117 (1.6)
Respiratory disease 456 (2.0) 149 (2.0)
Other 6623 (29.8) 2469 (32.7)
Data are presented as n (%) unless otherwise noted.
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inflammatory disease (Figs. 3 and 4). The estimates of
risk for all diseases were highest for cumulative dose
exposure in the last year and for current daily dose. The
estimates of death were highest for people with systemic
lupus erythematosus. Estimates from mixed and fixed-
effect models were similar except for the higher estimates
of Cushing syndrome for the cumulative dose in the last
year (adjusted HR 5 2.53; 95% CI: 2.38 to 2.67) (15).
Discussion
In this large population-based, retrospective cohort study
of 70,638 adults with chronic inflammatory diseases
typically treated with oral glucocorticoids, we found a
moderate incidence of but strong glucocorticoid dose-
response for adrenal insufficiency, Cushing syndrome,
and mortality. Specifically, for every increase in daily
dose of 5 mg, the risks increased by 7% for adrenal
insufficiency, 9% for Cushing syndrome, and 6% for
mortality. Likewise, a twofold increase or more in risk of
all outcomes was found for every increase in past year
cumulative dose of 1000 mg. The patterns of risk were
similar for the six diseases investigated, with higher point
risk estimates of adrenal adverse events observed in
people with systemic lupus erythematosus. The risk of
death was twice as high in patients with glucocorticoid-
induced adrenal dysfunction as in those not prescribed
glucocorticoids during the study period and in gluco-
corticoid users compared with nonusers during the study
period.
Previous studies have reported that glucocorti-
coid use is associated with higher incidence of adrenal
Table 7. Observation Time, Incidence Rates, and Incidence Rate Ratios of Death During the Study Period
Population Subgroup
Number of
Deaths
Person-y of
Follow-Up
IRR Compared
With Patients
Prescribed Oral
Glucocorticoids
IRR Compared With
Patients Not
Prescribed Oral
Glucocorticoids
All patients with prescribed oral GCs
(N 5 70,638)
22,317 451,146 NA 2.05 (1.99–2.10)
Patients with prescribed oral GCs not
presenting with adrenal adverse
events (N 5 70,211)a
22,132 447,656 NA 2.06 (2.00–2.11)
Patients with oral GC–induced Cushing
syndrome (N 5 248)
112 2072 1.09 (0.90–1.32) 2.24 (1.84–2.69)
Patients with oral GC–induced
adrenal insufficiency
(N 5 183)
74 1464 1.02 (0.80–1.28) 2.09 (1.64–2.63)
Patients not prescribed oral GCs
(N 5 41,166)
7544 312,049 — —
Values in parentheses in the last two columns indicate 95% CIs.
Abbreviations: GC, glucocorticoid; IRR, incidence rate ratio; NA, not applicable.
aExcluding patients who had adrenal insufficiency (n 5 183) or Cushing syndrome (n 5 248) during follow-up; four patients had both diagnoses recorded.
Figure 3. Time-variant cumulative and current dose-related oral glucocorticoid hazard ratios with 95% CIs for adrenal dysfunction by type of
chronic inflammatory disease. (A) Adrenal insufficiency. (B) Cushing syndrome. Estimates are adjusted for prescribed inhaled, intra-articular,
intramuscular, nasogastric, topical, and rectal glucocorticoids. HR, hazard ratio; IBD, inflammatory bowel disease; PMR/GCA, polymyalgia
rheumatica and/or giant cell arteritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; VAS, vasculitis.
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insufficiency (1, 8, 10) and Cushing syndrome symptoms
(11) in adults. However, to our knowledge, no study has
investigated the relationships between oral glucocorti-
coid dose and these clinically relevant outcomes.
According to findings from a meta-analysis including
3753 patients from 74 studies, 48.7% of patients with a
history of oral glucocorticoid use developed adrenal
insufficiency (1). More recent studies conducted in sec-
ondary and tertiary care also have reported higher
prevalence estimates of adrenal insufficiency in pa-
tients who are receiving glucocorticoid therapy (8, 28).
However, the incidence rates of adrenal insufficiency and
Cushing syndrome in our cohort were extremely low,
0.41 and 0.55 per 1000 person-years, respectively. This
most likely reflects a lack of awareness of adrenal in-
sufficiency in primary care and failure to code patients
taking glucocorticoids as having secondary Cushing
syndrome. Other potential reasons for this disparity
could be differences in case ascertainment and in the type
and severity of underlying diseases considered, resulting
in lower glucocorticoid exposure. Our study reflected
routine clinical practice, included patients with six
common chronic inflammatory diseases, and used di-
agnosis data recorded by physicians in primary care and
during hospital admissions. In contrast, the published
meta-analysis used clinical data from patients with al-
lergic diseases, cancer, and organ transplantation;
defined adrenal insufficiency accord-
ing to serum cortisol levels; and had
a mean daily prednisolone-equivalent
dose at the start of follow-up of 30 to
90 mg (compared with 17 mg in our
cohort).
To minimize misclassification of
non‒glucocorticoid-induced events in
our cohort, we used a highly stringent
definition of glucocorticoid-induced
adrenal dysfunction through imple-
mentation of an algorithm based on
diagnoses recorded in primary and
hospital care and the mortality registry
and prescribed medications. Episodes
of adrenal insufficiency diagnosed
and treated in accident and emer-
gency admissions but not requiring
hospitalization are therefore likely to
have been excluded from our study
if general practitioners did not code
the information in patient records.
Furthermore, 71% of diagnoses were
recorded during hospital admissions or
at death, and 83% of all cases of ad-
renal insufficiency occurred within
1 month of hospitalization or shortly after a consul-
tation with an endocrinologist; in addition, of 1343
patients receiving hydrocortisone during follow-up,
only 77 had a diagnosis of oral glucocorticoid-
induced adrenal insufficiency recorded. This suggests
that underdiagnosis and underrecording of adrenal
dysfunction is common in clinical practice. Indeed, in
our study, fewer than 1% of the 70,638 patients re-
ceiving oral glucocorticoids had adrenocorticotropic
hormone and cortisol testing results recorded in pri-
mary care. In addition, among patients who stopped
taking glucocorticoids before the end of follow-up and
did not restart the treatment (81% of patients), the
incidence of mortality following cessation of oral glu-
cocorticoid therapy markedly increased during the first
2 months after cessation and then rapidly decreased
over time after the first 3 months of interruption (15).
This is consistent with the existence of episodes of
undiagnosed adrenal crisis in clinical practice leading to
avoidable deaths.
Adrenal crisis remains a life-threatening complication
of glucocorticoid deficiency. Even in educated patients
with a diagnosis of primary and secondary adrenal in-
sufficiency, the incidence ranged between five and 10
crises per 100 person-years, with a 6% crisis-associated
mortality rate (29, 30). Our data highlight the critical
need for increased patient and health practitioner
Figure 4. Time-variant cumulative and current dose-related oral glucocorticoid hazard ratios
for death by type of chronic inflammatory disease. Estimates are adjusted for prescribed
inhaled, intra-articular, intramuscular, nasogastric, topical, and rectal glucocorticoids; baseline
asthma; cancer; heart failure; chronic kidney disease; and inflammatory diseases (time-variant).
All estimates were obtained among glucocorticoid users during the study period. HR, hazard
ratio; IBD, inflammatory bowel disease; PMR/GCA, polymyalgia rheumatica and/or giant cell
arteritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; VAS, vasculitis.
doi: 10.1210/jc.2019-00153 https://academic.oup.com/jcem 3765
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/104/9/3757/5475553 by U
niversity of Leeds user on 26 Septem
ber 2019
awareness of the real risk of adrenal crisis in this
situation—its clinical features, prevention, and treat-
ment. It is now timely to create and implement clear
diagnosis and management pathways to improve clinical
monitoring of patients treated with long-term gluco-
corticoid therapy.
The incidence of death found among glucocorticoid
users in our cohort is similar to the 23.4% estimate re-
ported in another study of patients with rheumatoid
arthritis treated with oral glucocorticoids that used a
similar methodology (12), but dose-response estimates
were lower. However, it is likely that some deaths caused
by adrenal insufficiency (e.g., among patients with epi-
sodes of acute illness such as infections) were missed and
were not reported as related to adrenal insufficiency. This
is also supported by the observed increased mortality rate
following treatment interruption that rapidly decreased
3 months after cessation.
The study has other limitations. First, although pre-
scribed medications are automatically recorded in the
CPRD, minimizing recording errors, the end date of the
prescriptions was not available in the data. This date
was therefore estimated from information recorded on
the product prescribed and the directions given to the
patient on how to take the drug; if missing, it was
imputed to estimate the period covered by the pre-
scription. Second, our data did not include prescriptions
issued by specialists in hospitals. We may have therefore
underestimated the dose taken by patients during the
period around diagnosis or at times of disease flare.
Third, we used oral glucocorticoid prescription as a
proxy for the actual intake of the drugs. However,
prescriptions reflect the actual dose taken only if ad-
herence is optimal. Fourth, although we implemented
strict algorithms to identify glucocorticoid-induced ad-
renal dysfunction, misclassification of diagnosis cannot
be completely ruled out.
Nonetheless, our study has important strengths. First,
we used linked electronic health records that spanned
primary and hospital care and were linked to the mor-
tality registry in England. Second, the sample size was
large and representative, allowing us to estimate risks
more precisely and improve generalizability, respectively.
Third, oral glucocorticoid dose was standardized (i.e.,
converted to prednisolone-equivalent dose), minimizing
risk of bias due to within- and between-patient variations
in prescribed glucocorticoids. Fourth, prescribed medi-
cations are automatically recorded in the CPRD, mini-
mizing recording errors. Fifth, to minimize length and
time-dependent bias, patient exposure status was taken
into account during analyses. Sixth, to minimize bias due
to confounding and overadjustment, we systematically
selected confounding variables and used statistical tools
(directed acyclic graphs) to address the problem. Seventh,
in addition to estimating glucocorticoid dose‒related
risks of death among patients treated with oral gluco-
corticoids during the study period, mortality was also
compared between oral glucocorticoid users and non-
users among patients diagnosed with the same chronic
inflammatory diseases.
In conclusion, in this study we quantified glucocor-
ticoid dose‒dependent risks of adrenal insufficiency,
Cushing syndrome, and death not previously reported.
Increased rates were still observed in patients taking the
equivalent of 5 mg of prednisolone per day. The observed
low incidence of reported adrenal dysfunction in patients
taking oral glucocorticoids and the increase in mortal-
ity following treatment interruption suggest lack of
awareness and need for both design and implementation
of clear diagnosis and management pathways and for
patient and health practitioner education to prevent
avoidable deaths.
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